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Misuse of statistics in medical and sports science research is common and may lead to detrimental 
consequences on health care. Most authors, editors, and peer reviewers of medical papers will not 
have expert knowledge of statistics or may be unconvinced about the importance of applying 
correct statistics in medical research. Although there are guidelines on reporting statistics in 
medical papers, a checklist on the more general and commonly seen aspects of statistics to assess 
when peer-reviewing an article is needed. In this article, we propose a CHecklist for statistical 
Assessment of Medical Papers (CHAMP) comprising 30 items related to the design, conduct, data 
analysis, reporting and presentation, and interpretation of a research paper. Whilst CHAMP is 
primarily aimed at editors and peer reviewers during the statistical assessment of a medical paper, 
we believe it will serve as a useful reference to improve authors' and readers' practice in their use 
of statistics in medical research. We strongly encourage editors and peer reviewers (and readers) 
to consult CHAMP for assessing manuscripts for potential publication, and authors to ensure the 
validity of the general statistical aspects of their papers and reporting medical research. 
 

















The misuse of statistics by implementing flawed methodology in medical and sports science 
research can lead to unreliable or even incorrect conclusions. The consequences of flawed 
methodology can have undesirable consequences on public health, patient management and athlete 
performance1. Unfortunately, errors in the study design, statistical analysis, reporting, and 
interpretation of results are common in medical journals2 3 and the quality of medical papers has 
been referred to as a scandal4.  
Sound methodology has been prioritized in the past decades, especially in high-impact factor 
journals. This is illustrated by the inclusion of more statistical editors and other methodologists 
(e.g. epidemiologists) in the review process. In addition, stakeholders in research have been 
encouraged to intensify their investments in statistical, epidemiological, and methodological 
education, such as training reviewers, providing online opportunities, developing (and extending) 
guidelines, and including methods content in regular scientific meetings5. There has also been a 
stronger emphasis on adherence to reporting guidelines (e.g., CONSORT, STROBE, STARD, 
REMARK and TRIPOD)6-10.  
Still, many medical and sports science journals do not involve statistical experts in the review 
process. This is unfortunate since the existence of basic statistical errors is more likely when 
authors, editors, and referees do not have sufficient knowledge of statistics and, worse, are 
unconvinced about the importance of correct statistics in medical research. Rarely do clinical 
journals systematically assess the use of statistics in submitted papers11 12. Thus, even after a paper 
is published in a scientific journal, it is necessary to read the content with some caution and pay 
careful attention to whether the statistical design and analysis were appropriate and the conclusions 
justified. Studies published in high-ranked journals are not immune from methodological or 
statistical flaws, which were not identified during the peer review process. Although some journals 
attempt to mitigate against such issues by using statisticians in the review process (as statistical 
reviewers or statistical editors), guidelines to assess methodological or statistical content in 
scientific papers would be useful when expert statistics reviewers are unavailable5 13 14.  
Whilst guidelines on how to report statistics in medical papers exist15 16, we propose a general 
checklist to judge the statistical aspects of a manuscript for peer review. While it is clearly 
impossible to cover everything, we believe it would be useful to have a basic checklist for assessing 
the statistical methods used more broadly within medical and sports science research papers. Based 
on an extensive revision of a previous checklist17, we describe a CHecklist for statistical 
Assessment of Medical Papers (CHAMP; Figure 1) comprising 30 items in the design, analysis, 
reporting and interpretation stages to aid the peer review of a submitted paper18.  
 
Explanation of the 30 items in the checklist 
The 30 items in the checklist were selected based on a previous BMJ checklist17, literature review, 
and experience of reviewing the statistical content of numerous papers submitted to a variety of 
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medical journals. The first author produced the checklist draft, the coauthors  suggested addition 
or removal of the items, and  all authors approved the final version. Other colleagues provided 
extensive comments on the paper and are listed in the Acknowledgments. Our checklist is not 
intended to, nor can it, cover all aspects of medical statistics. Our focus is rather on key issues that 
generally arise in clinical research studies. Therefore only important and common statistical issues 
encountered (including randomized controlled trials for which a separate checklist17 has been 
suggested before) were included in the CHAMP. Using our checklist requires some primary 
knowledge of statistics, however, we provide a brief explanation for each item to shed light upon 
the item, and cite the relevant references for further details. The first six items relate to the design 
and conduct of research, whereas items 7 to 16 deal with data analysis, items 17 to 23 with 
reporting and presentation, and finally items 24 to 30 with interpretation.  
 
ITEMS 1 – 7: DESIGN AND CONDUCT 
Item 1: Clear description of the goal of research, study objective(s), study design, and study 
population 
The research goal, study objectives, study design, and study and target populations must be clearly 
described so the editors of journals and readers can judge internal and external validity 
(generalizability) of the study. 
Being explicit about the goal of research is a prerequisite for good science regardless of the 
scientific discipline. For such clarification, a 3-fold classification of the research goal may be used: 
1) to describe; 2) to predict, which is equivalent to identifying “who” is at greater risk of 
experiencing the outcome; or 3) to draw a causal inference, which attempts to explain “why” the 
outcome occurs (e.g., investigating causal effects)5 19.  
The study objective refers to the rationale behind the study and points to the specific scientific 
question being addressed. For example, the objective of the HEx trial, a randomized controlled 
trial (RCT), was to evaluate the effect of heated water-based exercise training on 24-hour 
ambulatory blood pressure levels among resistant hypertensive patients20.The study objective is 
usually provided in the introduction after the rationale has been established.  
The study design refers to the type of the study, which is explained in the Methods section21. 
Examples of common study design include randomized controlled trials, cohort studies, case-
control studies or cross-sectional studies22. The study design should be described in details. In 
particular, the randomization procedure in randomized controlled trials, follow-up time for cohort 
studies, control selection for case-control designs, and sampling procedure for cross-sectional 
studies should be adequately explained6 7. As a general principle, the study design must be 
explained sufficiently so that another investigator would be able to repeat the study exactly.  
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The study population refers to the source population from which data are collected whereas the 
target population refers to the population to whom we are going to generalize the study results; the 
relationship between these two populations may be characterized using inclusion and exclusion 
criteria and is crucial for assessing generalizability. Returning to the Hex trial, the study population 
was restricted to persons whose ages were between 40 and 65 years with resistant hypertension for 
more than 5 years20. For both trials and observational studies it is very important to know what 
proportion of the source population is studied, and what proportion of the intended data set features 
in the analysis data set. For example, the source population may be all patients admitted to a 
hospital with a certain condition over a certain period of time. However, the analysis data set may 
only be 50% of this, for various reasons such as patents refusing consent, measurements not taken, 
patients dropping out etc. For example in the HEX trial they had to screen 125 hypertensive 
patients to find 32 who met the inclusion criteria. This has some bearing on to whom heated-water 
based exercise training can be given and how likely it is to be relevant to other practitioners20 
Item 2: Clear descriptions of outcomes, exposures/treatments and covariates, and their 
measurement methods 
All variables considered for statistical analysis should be stated clearly in the paper, including 
outcomes, exposures/treatments, predictors and potential confounders/mediators/effect-measure 
modifiers. The measurement method and timing of measurement for each of these variables should 
also be specified. If the goal of the research is to draw a causal inference via observational studies, 
authors should also visualize their causal assumptions in a diagram23 24. To exemplify the concept, 
in an observational cohort study evaluating the effect of physical activity on functional 
performance and knee pain in patients with osteoarthritis25, physical activity (exposure) was 
measured using the Physical Activity Scale for the Elderly, and functional performance and self-
reported knee pain (outcomes) were measured by the Timed 20-meter Walk Test and the Western 
Ontario and McMaster Universities Osteoarthritis Index, respectively. Furthermore, depressive 
symptoms were considered as a potential confounder and measured using the Center for 
Epidemiologic Studies Depression Scale. All variables mentioned were measured at baseline and 
also in three annual follow-up visits25. 
Item 3: Validity of study design 
The design should be valid i.e., it should match the research question and also should not introduce 
bias in the study results.  For example, an editor should be able to assess whether the controls in a 
case-control study were adequately representative of the source population of the cases. 
Alternatively, in a clinical trial, it can be asked, first if there was one (or more) control groups and 
if so, if patients were randomized to treatment or control, and if so, whether the randomization 
method and allocation concealment were appropriate? 
Item 4: Clear statement and justification of sample size 
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The manuscript should have a section clearly justifying the sample size26. When a sample size 
calculation is warranted, the sample size section should be described in enough detail to allow 
replication of the estimate, along with a clear rationale (supported by references) on choice of 
values used in the calculation, the outcome for which the calculation is based on, including the 
minimum clinically important effect size27 28 . For example, typical sample size calculations aim 
to ensure the study enjoys a sufficiently large precision for estimates of occurrence measures such 
as risk or association measures like risk ratio29 30, or that there is an adequate power to detect 
genuine effects if they exist (statistical tests). Attrition/lost-to-follow-up/non-response and design 
effects (e.g., due to clustering) should be taken into consideration. Some guidance for sample size 
calculation also exist in other areas, such as prediction model development and validation31-33. 
Item 5: Clear declaration of design violations and acceptability of the design violations 
Design violations frequently occur in practice. Non-response in surveys, censoring (loss-to-follow-
up or competing risks) in prospective studies34, and non-compliance with the study treatments in 
randomized controlled trials should be declared explicitly in the paper35. Given validity of the 
design, the acceptability of violations should be assessed. For example, was an observed non-
response/censoring proportion too high; what were the reasons for data loss, and is this level 
acceptable to achieve the scientific goals of the study? 
Item 6: Consistency between the paper and its previously published protocol 
The reviewer should identify inconsistencies with any published protocol (and where relevant, 
registry information) in terms of important features of the study including sample size, 
primary/secondary/exploratory outcomes, and statistical methods. 
 
ITEMS 7 - 16: DATA ANALYSIS 
Item 7: Correct and complete description of statistical methods 
A separate part in the Methods section of the manuscript should be devoted to the description of 
the statistical procedures. Both descriptive and analytic statistical methods should sufficiently 
described so that the methods can be assessed by a statistical reviewer to judge their suitability and 
completeness in addressing the study objectives. 
Item 8: Valid statistical methods used and assumptions outlined  
The validity of statistical analyses relies on some assumptions. For example, the independent t-
test for the comparison of two means requires three assumptions: independence of the 
observations, Normality, and homogeneity of variance. As another example, all expected values 
for a chi-square test must be more than 1, and at most 20% of the expected values can be less than 
5. These statistical assumptions should be judged as a matter of context or assessed using 
appropriate methods such as a Normal probability plot for checking the Normality assumption36. 
In this regard, an alternative statistical test should be applied if some assumptions are clearly 
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violated. It should be noted that some statistical tests are robust against mild to moderate violations 
of some assumptions. For the t-test, lack of Normality and lack of homogeneity of variance do not 
necessarily invalidate the t-test, whereas lack of independence of the outcome variables will imply 
the results are invalid37. It has been demonstrated that independent t-test can be valid, but 
suboptimal for the Likert ordinal data even with a sample size of 2038. 
An important but often ignored aspect in practice is that ratio estimates like the estimated odds 
ratio, risk ratio and rate ratio are biased away from the null value. This bias is amplified with sparse 
data known as sparse-data bias39. A sign of sparse data is an unrealistically large ratio estimate or 
confidence limit which is simply an artifact of sparse data. For example, an OR>10 for a non-
communicable disease should be considered as a warning sign for sparse-data bias. In the extreme, 
an empty cell leads to an absurd OR estimate of infinity, known as separation40. Special statistical 
methods such as penalization or Bayesian methods must be applied to decrease the sparse-data 
bias40 41. Some other important considerations in statistical analysis are: 
i) accounting for correlation in the analysis of correlated data (e.g., variables with repeated 
measurements in longitudinal studies42, cluster randomized trials43, and complex surveys44); 
ii)matching in the analysis of matched case-control and cohort data45 46; 
iii)ordering of several groups in the analysis; 
 iv) censoring in the analysis of survival data; 
v) adjusting for baseline values of the outcome in the analysis of randomized clinical trials27; 
vi)correct calculation and interpretation of population attributable fraction47 48; 
vii) and adjusting for overfitting using shrinkage or penalization methods when developing a 
prediction model49 50. 
Item 9: Appropriate assessment of treatment effect or interaction between treatment and another 
covariate 
Appropriate statistical tests should be used for the assessment of treatment effects and potential 
interactions. Assessment of overlapping treatment group-specific confidence intervals can be 
misleading51-53. Thus, the comparison of the confidence intervals of the treatment groups should 
not be used as an alternative to the statistical test of treatment effect. Moreover, comparing P-
values for the treatment effect at each level of the covariate (e.g., men and women) should not be 
used as an alternative for an interaction test between the treatment and covariate. For example  in 
the case of observing P-value<0.05 and P-value>0.05 in the levels one might incorrectly conclude 
that gender was a statistically significant predictor of outcome54. Similarly, we cannot conclude 
no effect modification if the confidence intervals of the subgroups are overlapping55. 
Item 10: Correct use of correlation and associational statistical testing 
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The misuse of correlation and associational statistical testing is not uncommon. As an example, 
correlation should not be used for assessing the agreement between two methods in methods-
comparison studies56. To see why, two measures of X and Y are perfectly correlated but in poor 
agreement if X=2Y, but they are in poor agreement because X is twice Y. Likewise, we cannot 
infer that two methods agree well because the P-value is large enough using the statistical testing 
of the means such as paired t-test. In fact, a high variance of differences indicates poor agreement 
but also increases the chance that the paired t-test will result in a large P-value and thus the methods 
will appear to agree1.  
Item 11: Appropriate handling of continuous predictors 
Reviewers should be wary of studies that have dichotomized or categorized continuous variables 
– this should be generally avoided.57. Bias, inefficiency and residual confounding may also result 
from dichotomizing/categorizing a continuous variable and using it as a categorical variable in a 
model. Continuous variables should be retained as continuous and their functional form be 
examined, as a linearity assumption may not be correct. Approaches for handling continuous 
predictors include fractional polynomials or regression splines57-60.  
Item 12: Confidence intervals do not include impossible values 
A valid confidence interval should exclude impossible values. For instance, a simple Wald 
confidence interval for a proportion (𝑃 ± 1.96√𝑃(1−𝑃)𝑛  ) is not valid when P is close to 0 or 1, and 
may yield negative values outside the possible range for a proportion (0≤P≤1)61. To remedy such 
conditions, the Wilson score or Agresti-Coull interval can be applied6. 
Item 13: Appropriate comparison of baseline characteristics between the study arms in 
randomized trials 
In a randomized clinical trial, any baseline characteristic difference between groups should be due 
to chance (or unreported bias). Reviewers should look out for any statistical testing at the baseline 
as reporting P-values does not make sense62. The decision on which baseline characteristics 
(prognostic factors) are included in any adjustment should be pre-specified in the protocol and 
based on the subject-matter knowledge, not on P-values. The differences between groups in 
baseline characteristics should be identified by their size and discussed in terms of potential 
implications for the interpretation of the results 
Item 14: Correct assessment and adjustment of confounding 
An important goal of health research is drawing a causal inference. Here, the interest is in the 
causal effect of an exposure on the outcome. The major source of bias threatening causality studies, 
including observational studies as well as randomized studies (with small-to-moderate sample 
size), is confounding63-65. Confounding can be controlled in the design phase (e.g., through 
restriction or matching) or analysis phase (e.g., using regression models or propensity score 
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methods)66 67. Selection of confounders should be based on priori causal knowledge, often 
represented in the causal diagrams23 68-70, not p-values (e.g., using stepwise approaches). 
Automated statistical procedures, such as stepwise regression, do not discriminate between 
confounders and other covariates like mediators or colliders which should not be adjusted for in 
the analysis. Moreover, stepwise regression is only based on the association between confounders 
and outcome, and disregards the association between the confounders and exposure. Thus, 
stepwise procedures should not be used for confounder selection. In practice, many confounders 
(and exposures and outcomes)71 72 are time-varying, and the so-called “causal methods” should be 
applied for the appropriate adjustment of time-varying confounders73. Similarly, in studies 
evaluating the prognostic effect of a new variable, adjustment for existing prognostic factors 
should be routinely performed, and variable selection of the existing factors is not generally 
needed49. 
 
Item 15: On-support inference i.e., no model extrapolation to the region not supported by data 
The goal of interest in many health studies is predicting an outcome from one or more explanatory 
variables using a regression model. The model is valid only within the range of observed data on 
the explanatory variables, and we cannot make prediction for people outside the range. This is 
known as model extrapolation74. Suppose we have found a linear relation between body mass index 
(BMI) and blood pressure (BP) based on the following equation: 𝐵𝑃 = 𝐴 + 𝐵 ∗ (𝐵𝑀𝐼) 
Now the intercept, A, cannot be interpreted since it corresponds to the blood pressure for a person 
with BMI of zero! The remedy is centering BMI and including the centered variable (BMI – 
average BMI) in the model so that the intercept refers to the blood pressure for a person with the 
average BMI in the population. 
As another example, suppose the following linear relation holds in a randomized controlled trial: 𝐵𝑃 = 𝐴 + 𝐵 ∗ (𝑇𝑅𝑇) + 𝐶 ∗ (𝐵𝑀𝐼) + 𝐷 ∗ (𝑇𝑅𝑇 ∗ 𝐵𝑀𝐼) 
where TRT denotes treatment (1: intervention, 0: placebo) and TRT*BMI is the product term 
(interaction term) between treatment and BMI. In this model, the parameter B cannot be interpreted  
on its own because it is the mean difference in blood pressure between two treatment groups for a 
person with BMI of zero. Again, the solution is centering BMI and including centered BMI, and 
product term between TRT and centered BMI in the model so that the B′ (coefficient of TRT in 
the new model) refers to the mean difference in blood pressure for a person with the average BMI 
in the population. 
Item 16: Adequate handling of missing data 
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The methods used for handling missing data should be described and justified in relation to stated 
assumptions about the missing data (missing completely at random, missing at random, and 
missing not at random), and sensitivity analyses must be done if appropriate. Missing data75 can 
introduce selection bias and should be handled using appropriate methods such as multiple 
imputation76 and inverse probability weighting77. Naïve methods such as complete-case analysis, 
single imputation using the mean of the observed data, last observation carried forward, and the 
missing indicator method are statistically invalid in general and they can lead to serious bias78. 
 
ITEMS 17 - 23: REPORTING AND PRESENTATION 
Item 17: Adequate and correct description of the data 
, The mean and standard deviation provide a satisfactory summary of data for continuous variables 
that have reasonably a symmetric distribution. The standard error (SE) is not a sound choice to be 
used in place of SD79.  A useful memory aid is to use standard Deviation to Describe Data and 
standard Error to Estimate parameters (Campbell MJ and Swinscow,TDV  Statistics st Square One, 
London: BMJ Books 2009)  Besides, “mean ± SD” is not suitable since it implies the range in 
which 68% of data are, not a relevant concept we are looking for, and “mean(SD)” should be 
reported instead1. In case of having highly skewed quantitative data, median and interquartile range 
(IQR) are more informative summary statistics for description. It should be noted that the mean/SD 
ratio<2 for positive variables is a sign of skewness80. Categorical data should be summarized as 
number and percentage81. For cohort data, a summary of follow-up time such as median and IQR 
should be reported. 
Item 18: Descriptive results provided as occurrence measures with confidence intervals, and 
analytic results provided as association measures and confidence intervals along with P-values 
The point estimates of the occurrence measures, for instance, prevalence, risk and incidence rate 
with 95% confidence intervals should be reported for descriptive objectives81. Alternatively, the 
point estimates of the association measures, for instance odds ratio, risk ratio and rate ratio with 
95% confidence intervals along with P-values should be reported for analytic objectives as part of 
the results section82. 
Item 19: Confidence intervals provided for the contrast between groups rather than for each group 
For analytic studies like randomized controlled trials, the 95% confidence intervals should be 
given for the contrast between groups rather than for each group6. For the blood pressure example 
mentioned above20, the authors reported  the mean of blood pressure with 95% confidence interval 
in each group but they should also have given themean difference in 24-hour ambulatory blood 
pressure levels between groups with 95% confidence interval since the aim of the trial was to 
compare treatment with control, not just report treatment and control outcomese. 
Item 20: Avoiding selective reporting of analyses and P-hacking 
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All statistical analyses performed should be reported regardless of the results. P-hacking, playing 
with data to produce desired P-value (upward as well as downward), must be avoided83-85. This is 
probably difficult to assess as a reader/reviewer, but usually one would be clued in if there are 
many more analyses than those stated in the objectives or only statistically significant comparisons 
are presented when a larger pool of variables were identified in the methods. 
Item 21: Appropriate and consistent numerical precisions for effect sizes, test statistics, and P-
values, and reporting the P-values rather their range 
P-values should be reported directly with one or two significant figures even if they are greater 
than 0.05, e.g., as P-value=0.09 or P-value=0.28. One should not focus on “statistical significance” 
or dichotomize P-values (eg p<0.05)86-88 or express them as “0.000” or “NS”. Nonetheless, 
spurious precision, too many decimals, in numerical presentation should be avoided89 90. For 
example, typically P-values less than 0.001 can be written as <0.001 without harm, and it does not 




Item 22: Providing sufficient numerical results that could be included in a subsequent meta-
analysis 
Meta-analyses of randomized trials and observational studies provide high levels of evidence in 
health research. Providing numerical results in individual studies contributing to subsequent meta-
analysis is of special importance. Follow-up score and change score from the baseline are two 
possible approaches which can be applied to estimate treatment effect in randomized controlled 
trials91. While the follow-up score meta-analysis requires after-intervention mean and SD in two 
groups of intervention and placebo, the mean and SD of differences from the baseline are 
prerequisite for performing change-score meta-analysis. However, authors often only report mean 
and SD before and after intervention. The mean of the difference in each group can be calculated 
from the difference of the means, but calculating the SD of differences needs a guessed group-
specific correlation between baseline and follow-up scores besides before- and after-intervention 
SD. 
Item 23: Acceptable presentation of the figures and tables 
Tables and figures are effective data presentation that should be properly managed92-95. Figures 
should be selected based on the type of variable(s) and appropriately scaled. The error bar graph 
as an illustration, can be used for displaying the mean and confidence interval. It is inappropriate 
to give s bar chart with a SE bar superimposed instead ( a so called ‘dynamite plunger plot94) . 





ITEMS 24 - 30: INTERPRETATION 
Item 24: Interpreting the results based on association measures and 95% confidence intervals 
along with P-values, and correctly interpreting large P-values as indecisive results, not evidence 
of absence of an effect 
The study results should be interpreted in light of the point estimate and appropriate association 
measures such as mean difference and 95% confidence interval as well as precise P-values. When 
testing a null hypothesis of no treatment effect, the P-value is the probability the statistical 
association would be as extreme as observed or more extreme, assuming that null hypothesis and 
all assumptions used for the test are correct. P-values for non-null effect sizes can also be 
computed. The point estimate is the effect size most compatible with the data in that it has P-
value=1.00, while the 95% confidence interval shows the range of effect sizes reasonably 
compatible with the data in the sense of having P-value>0.0587. We should judge the clinical 
importance and statistical reliability of the results by examining both of the 95% confidence limits 
as well as looking at precise P-values, not just whether a P-value crosses a threshold or not27 96. It 
is incorrect to interpret P-value>0.05 as showing no treatment effect; instead it represents an 
ambiguous outcome97 98. It is not evidence that the effect is unimportant (“absence of evidence is 
not evidence of absence”); inferring unimportance requires that every effect size inside the 
confidence interval be considered unimportant87. 
Item 25: Using confidence intervals rather than post-hoc power analysis for interpreting the 
results of studies 
Conceptually, it is not valid to interpret power as if it pertains to the observed study results99-101. 
Rather, power should be treated as part of study rationale and design before actual conduct begins, 
e.g., as in sample size calculations. Power does not correctly account for the observations that 
follow; for example, a study could have high power and observe a high P-value, yet still favor the 
alternative hypothesis over the null hypothesis101. The precision of results should be gauged using 
confidence intervals.  
Item 26: Correctly interpreting occurrence or association measures 
It will be crucial to interpret occurrence and association measures correctly. Odds ratios commonly 
provide examples of misinterpretation: if the event is rare, they can approximate risk ratios but 
they are not conceptually the same and will differ considerably if the event is common102. In a 
study with a risk of 60% in an exposed group and 40% in an unexposed group, the error in 
interpreting the odds ratio (2.25) as a risk ratio (1.5) is considerable. Prevalence in cross-sectional 
studies is another example, which sometimes has been incorrectly called ‘risk’. 
Item 27: Distinguishing causation from association and correlation 
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We should be cautious about the correct use of the technical terms such as effect, association and 
correlation. Association, meaning no independence, does not imply causation (and effect). Causal 
effect estimation requires measurement of exposure before outcome (temporality) as well as 
confounding adjustment. The correlation refers to a monotonic association between two variables. 
Therefore, no correlation does not imply no association. 
Item 28: Results of pre-specified analyses are distinguished from the results of exploratory 
analyses in the interpretation 
The results obtained from the pre-specified (a priori) analyses which have been already designed 
and mentioned in a protocol are much more reliable than the results obtained after data dredging 
(data-derived or post-hoc analyses). 
Item 29: Appropriate discussion of the study methodological limitations 
The methodological limitations of the study design and analysis should be discussed. Ideally, the 
probabilistic bias analysis, in which a probability distribution is assumed for the bias parameters, 
and bias is probabilistically accounted for using Monte-Carlo sensitivity or Bayesian analysis, 
should be performed for adjustment of uncontrolled confounding (e.g., due to an unmeasured 
confounder), selection bias (e.g., through missing outcome data) and measurement bias (e.g., 
subsequent to measurement error in the exposure)103-105. The authors should at least qualitatively 
discuss the main sources of bias and their impact on the study results106 107.  
Item 30: Drawing only conclusions supported by the statistical analysis and no generalization of 
the results to subjects outside the target population 
The study interpretation must be based not only on the results but also in the light of the study 
population as well as any limitation in the design and analysis74. For example, if the study has been 
done in women, it cannot be necessarily generalized to the population of men and women. 
 
Conclusion 
The importance role of good statistic and sound methodology in medical research cannot be 
overstated. We strongly encourage authors to adhere to CHAMP for carrying out and reporting 
medical research, and to editors and reviewers for well-evaluating manuscripts for potential 
publication. We have only covered some basic items, and each type of study or statistical model 
(e.g., randomized trial, prediction model) has their own issues that ideally require statistical 
expertise. We appreciate that for some items in the checklist there is no unequivocal answer, and 
thus assessing the statistics of a paper may involve some subjectivity. Moreover, the questions in 
the checklist are not equally important e.g., papers with serious errors in design are statistically 
unacceptable regardless of how the data were analyzed, and aspects of presentations are clearly 
less important than other aspects. It is important to note that, statistical review, carried out by 
experienced statisticians, is the preferred way of reviewing statistics in research papers, more so 
14 
 
than what any checklist can achieve. We hope CHAMP improves authors' practice in their use 
of statistics in medical research and serve as a useful handy reference for editors and referees during 
the statistical assessment of medical papers. 
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Design and conduct  
1. Clear description of the goal of research, study objective(s), study 
design, and study population 
Yes Unclear No 
2. Clear descriptions of outcomes, exposures/treatments and 
covariates, and their measurement methods 
Yes Unclear No 
3. Validity of study design Yes Unclear No 
4. Clear statement and justification of sample size Yes Unclear No 
5. Clear declaration of design violations and acceptability of the 
design violations  
Yes Unclear No 
6. Consistency between the paper and its previously published 
protocol 
Yes Unclear No 
Data analysis     
7. Correct and complete description of statistical methods Yes Unclear No 
8. Valid statistical methods used and   assumptions outlined Yes Unclear No 
9. Appropriate assessment of treatment effect or interaction between 
treatment and another covariate 
Yes Unclear No 
10. Correct use of correlation and associational statistical testing  Yes Unclear No 
11. Appropriate handling of continuous predictors  Yes Unclear No 
12. Confidence intervals do not include impossible values Yes Unclear No 
13. Appropriate comparison of baseline characteristics between the 
study arms in randomized trials  
Yes Unclear No 
14. Correct assessment and adjustment of confounding  Yes Unclear No 
15. On-support inference i.e., no model extrapolation to the region not 
supported by data 
Yes Unclear No 
16. Adequate handling of missing data Yes Unclear No 
Reporting and presentation    
17. Adequate and correct description of the data Yes Unclear No 
18. Descriptive results provided as occurrence measures with 
confidence intervals, and analytic results provided as association 
measures and confidence intervals along with P-values 
Yes Unclear No 
19. Confidence intervals provided for the contrast between groups 
rather than for each group  
Yes Unclear No 
20. Avoiding selective reporting of analyses and P-hacking Yes Unclear No 
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21. Appropriate and consistent numerical precisions for effect sizes, 
test statistics, and P-values, and reporting the P-values rather their 
range 
Yes Unclear No 
22. Providing sufficient numerical results that could be included in a 
subsequent meta-analysis  
Yes Unclear No 
23. Acceptable presentation of the figures and tables  Yes Unclear No 
Interpretation    
24. Interpreting the results based on association measures and 95% 
confidence intervals along with P-values, and correctly interpreting 
large P-values as indecisive results, not evidence of absence of an 
effect  
Yes Unclear No 
25. Using confidence intervals rather than post-hoc power analysis for 
interpreting the results of studies 
Yes Unclear No 
26. Correctly interpreting occurrence or association measures Yes Unclear No 
27. Distinguishing causation from association and correlation  Yes Unclear No 
28. Results of pre-specified analyses are distinguished from the results 
of exploratory analyses in the interpretation 
Yes Unclear No 
29. Appropriate discussion of the study methodological limitations Yes Unclear No 
30. Drawing only conclusions supported by the statistical analysis and 
no generalization of the results to subjects outside the target 
population 
Yes Unclear No 
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